Sugi Predict

Sugi Predict / Compounds / SCHEMBL16740359

SCHEMBL16740359

SCHEMBL16740359

Cc1nc2cc(F)c(F)cc2n1-c1cc(C#N)cc(Nc2ccc(Cl)cc2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 4/20 0.37
▸ MAPT P10636 2/20 0.37
▸ LMNA P02545 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ XBP1 P17861 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ ATM Q13315 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ NPC1 O15118 3/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ AGPAT2 O15120 2/20 0.35
▸ ABCG2 Q9UNQ0 3/20 0.35
▸ MAP3K14 Q99558 1/20 0.35
▸ BMI1 P35226 2/20 0.35
▸ TP53 P04637 1/20 0.34
▸ DHFR P00374 1/20 0.34
▸ PIK3CD O00329 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16739959 0.92 SLC2A1 (0.41) RAB9AMAPTLMNAKDM4EPOLB
SCHEMBL16740399 0.89 BMI1 (0.46) RAB9AMAPTPOLBNPC1CYP1A2
SCHEMBL16739963 0.88 BMI1 (0.48) AGPAT2ABCG2BMI1
SCHEMBL16740025 0.88 TUBB4A (0.42) RAB9AMAPTLMNAKDM4EMAPK1
SCHEMBL16740272 0.85 BMI1 (0.50) LMNABMI1USP2ALDH1A1NPSR1
SCHEMBL16740408 0.85 IDH1 (0.44) LMNABMI1DHFRUSP2ALDH1A1
SCHEMBL16747953 0.85 NPC1 (0.43) RAB9AMAPTNPC1CYP1A2CYP3A4
SCHEMBL16740163 0.84 ABCG2 (0.37) RAB9AMAPTLMNAKDM4EPOLB
SCHEMBL16739717 0.83 EGFR (0.40) RAB9AMAPTNPC1CYP1A2CYP3A4
SCHEMBL16740255 0.82 BMI1 (0.48) AGPAT2MAP3K14BMI1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 — — US claimed
EP-3071553-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC Therapeutics, Inc. (US) 2016-09-28 — — EP claimed
WO-2015076800-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 — — WO claimed
US-10584115-B2 Substituted pyridine and pyrazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2020-03-10 — — US disclosed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 — — US disclosed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 — — US disclosed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 — — US disclosed
WO-2015076800-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B RAB9A 3343/4885MAPT 4561/4885LMNA 3602/4885
US-10584115-B2 Substituted pyridine and pyrazine BMI-1 inhibitors BMI1, BAZ2A, BAZ2B RAB9A 3343/4885MAPT 4561/4885LMNA 3602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.